Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Zeev's Turnips - No Politics -- Ignore unavailable to you. Want to Upgrade?

To: Zeev Hed who wrote (90076)	7/2/2002 2:02:37 PM
From: Bob Biersack	Respond to of 99280

Issue comes under pressure in reaction to JP Morgan pre-market note on Genentech (DNA -3%). Firm believes that DNA's Rituxan program on rheumatoid arthritis is moving forward. JP Morgan thinks IDEC will drop development of IDEC-151 and instead work exclusively on developing Rituxan for rheumatoid arthritis. Says IDEC-151 has been associated with transient rash historically, and this side effect appears to continue to be a problem in latest drug trial.

To: Zeev Hed who wrote (90076)	7/2/2002 2:03:05 PM
From: Smart_Money	Read Replies (1) \| Respond to of 99280

2:22pm around the corner.

To: Zeev Hed who wrote (90076)	7/2/2002 2:03:27 PM
From: anthonydp	Read Replies (1) \| Respond to of 99280

IDPH jpm thinks co will drop development od idec-151 (before open)